The direct overseas offering and listing by domestic entities refers to the overseas offering and listing by joint-stock companies registered and incorporated domestically in China (the "Direct Overseas Listings"), which is currently one of the main ways for domestic entities to be listed overseas.

Following the economic and financial crisis in 2007, in view of the significant weakness in the resiliency of banks and other market participants to financial and economic shocks, in particular from over-the-counter (OTC) derivatives transactions...

In "Interpretation of China's Annual Drug Review Report (2015-2021) - Review of the Achievements of China's Drug Review and Approval System Reform (Part 1)"...

Crypto currencies (also known as crypto assets) have seen rapid development since Bitcoin's emergence during the financial crisis in 2008.

近年来，我国不断探索对LDT的监管。随着一系列新规的出台，有众多优秀的跨国及本土公司均参与到该领域的研究中...

此外，由于中国反制措施没有提供针对医药行业的特定豁免，预计未来一段时间内美国进口药价格将会持续走高，对此应当做好全面的准备。

License-in/out is a common transaction model in the pharmaceutical field in recent years, that is, the licensor licensees the relevant R&D technology and patents...

In the process of overseas offering and listing of domestic enterprises so far, it is necessary for the listing intermediaries (the "Intermediaries") to conduct due diligence on all aspects of the issuer.

On February 4, 2024, our country's National Medical Products Administration (NMPA) released the 2023 Annual Drug Review Report on its official website.

数据中心与智算中心作为云服务和AI算力的物理基础，正面临从传统机房向综合基础设施的演进。在"东数西算"政策推进和绿色低碳约束趋严的背景

2022年5月9日，国家药监局发布《药品管理法实施条例（修订草案征求意见稿）》（简称"《征求意见稿》"），向社会公开征求意见，征求意见反馈截止

随着人类遗传资源、生物安全、实验动物等领域的监管不断完善，近年来，科技部的执法行动亦随之趋于活跃与细致。

License-in/out has become the most common way for innovative drug and medical device (including medical aesthetic) companies to collaborate on the development of related technologies...

On December 1, 2019, the Drug Administration Law and the Vaccine Administration Law officially came into effect, and the relevant regulations adjusted the management...

Recently, the China Banking and Insurance Regulatory Commission ("CBIRC") issued the Measures for Regulatory Assessment of Corporate Governance of Banking and Insurance Institutions...

On December 30, 2022, the Asset Management Association of China ("AMAC") issued a consultation draft of the Measures for Registration and Filing of Private Investment Funds...

On February 27, 2023, the National Health Commission, together with the Ministry of Education, the Ministry of Science and Technology, and the State Administration of Traditional Chinese Medicine...

China's new exit and entry regulations introduce significant changes affecting technical personnel, individuals with cross-border assets, public officials, and intermediary service providers. The provisions strengthen authenticity reviews, connect technology export controls with travel restrictions, and establish a comprehensive framework for managing cross-border movement while balancing national security with legitimate international activities.

2023年5月9日，国家卫健委科教司发布《体细胞临床研究工作指引（征求意见稿）》（" 《征求意见稿》"），并面向社会公开征求意见。体细胞治疗

近日，中国银行保险监督管理委员会（"银保监会"）发布《银行保险机构公司治理监管评估办法》（银保监规[2022]19号）（"2022年办法"）[1]。银保监会于2